Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 52 clinical trials
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

daratumumab, bortezomib, dexamethasone, and thalidomide or lenalidomide. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Bortezomib is a drug that

multiple myeloma
hypercalcemia
serum calcium
bone lesion
daratumumab
  • 5 views
  • 20 Jun, 2021
  • 1 location
Effect of Memantine on Radiotherapy-related Cognitive Impairment

Purpose: This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the therapeutic effects of thalidomide in radiotherapy-related cognitive impairment. Further

memantine
cancer
  • 1 views
  • 23 Jan, 2021
  • 1 location
Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases

used to evaluate hydroxychloroquine, thalidomide, glucocorticoids, is considered the gold standard technology to qualitative and quantitative analysis of drugs in blood and its comparison with the

tumor necrosis factor
biologics
rheumatic diseases
cutaneous lupus
autoimmune disease
  • 40 views
  • 26 Jan, 2021
  • 2 locations
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients

inflammation plays a crucial role in the cause and effects of AD neuropathology. Capitalizing on the experience from a previous clinical trial with thalidomide, here, the investigators hypothesize that

memantine
dementia
mental state examination
cholinesterase inhibitors
depression
  • 0 views
  • 04 Jun, 2021
  • 1 location
Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis

regimens between bortezomib-thalidomide-dexamethasone (BTD) and bortezomib-cyclophosphamide-dexamethasone (BCD) in the treatment of AL amyloidosis, so as to provide more clinical evidence for the standard

thalidomide
bortezomib
electrophoresis
cyclophosphamide
bone marrow procedure
  • 0 views
  • 26 Jan, 2021
  • 1 location
The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

determine: Overall survival Time to disease progression The overall response rate following ixazomib, thalidomide and dexamethasone (ITD) re-induction Time to

proteasome inhibitor
ejection fraction
vasectomy
progressive disease
melphalan
  • 710 views
  • 22 Jan, 2021
  • 78 locations
STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

not eligible for autologous stem cell transplantation (ASCT): bortezomib-melphalan-prednisone (VMP), melphalan-prednisone- thalidomide (MPT) and lenalidomide with low-dose dexamethasone (Rd).

plasmacytoma
hypercalcemia
ejection fraction
serum calcium
bone lesion
  • 4 views
  • 10 May, 2021
  • 1 location
Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy

This is a randomized, 2-arm phase II, multi-center study to evaluate the overall response rate in newly diagnosed, transplant ineligible patients receiving 9 cycles induction therapy with either KTd or KRd followed by randomization to either carfilzomib maintenance treatment for 12 months or to observation only. Maintenance is given for …

ejection fraction
serum proteins
bone marrow procedure
growth factor
lenalidomide
  • 68 views
  • 30 May, 2021
  • 25 locations
R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of R-CHOP (Rituximab-Cyclophosphamide, Epirubicin, Vincristine and Prednisone) combined with lenalidomide in the first-line treatment for patients with medium to high risk/high risk diffuse large B cell lymphoma.

rituximab
cyclophosphamide
prednisone
lenalidomide
vincristine
  • 0 views
  • 22 Aug, 2021
  • 1 location
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I Stage II or Stage III Multiple Myeloma

RATIONALE: Drugs used in chemotherapy, such as melphalan, use different ways to stop cancer cells from dividing so they stop growing or die. Stem cell transplant using stem cells from the patient may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. Giving …

  • 19 views
  • 07 Nov, 2020
  • 3 locations